Pentraxin 3 in patients with severe sepsis or shock: the ALBIOS trial

Pietro Caironi, Serge Masson, Tommaso Mauri, Barbara Bottazzi, Roberto Leone, Michela Magnoli, Simona Barlera, Filippo Mamprin, Andrea Fedele, Alberto Mantovani, Gianni Tognoni, Antonio Pesenti, Luciano Gattinoni, Roberto Latini, Paola Bruzzone, Francesca Pagan, Riccarda Russo, Andrea Confalonieri, Chiara Abbruzzese, Beatrice VergnanoStefano Faenza, Antonio Siniscalchi, Elisabetta Pierucci, Andrea Noto, Angelo Pezzi, Paolo Spanu, Vieri Parrini, Roberto Oggioni, Giovanni Stefano Pasetti, Maria Cinzia Casadio, Rosa Buontempo, Sara Carrer, Francesca Piccoli, Tatiana Rizzi, Anselmo Caricato, Monica La Sala, Alessandra Antonaci, Paola Fassini, Silvia Paganini, Virginia Porta, Gabriella Moise, Silvia Marell, Mirella Furia, Maria Cristina Urbano, Roberta Carobbi, Simona Poleni, Andrea Ballotta, Roberto Colombo, Giuseppe Maggio, Francesco Bona, the ALBIOS Biomarkers Study Investigators

Research output: Contribution to journalArticlepeer-review


Background: The long pentraxin PTX3 is a key component of the humoral arm of innate immunity related to sepsis severity and mortality. We evaluated the clinical and prognostic significance of circulating PTX3 in the largest cohort ever reported of patients with severe sepsis or septic shock. Materials and methods: Plasma PTX3 was measured on days 1, 2 and 7 after randomization of 958 patients to albumin or crystalloids for fluid resuscitation in the multicentre Albumin Italian Outcome Sepsis (ALBIOS) trial. We tested the association of PTX3 and its changes over time with clinical severity, prevalent and incident organ dysfunctions, 90-day mortality and treatment. Results: PTX3 was high at baseline (72 [33–186] ng/mL) and rose with the severity and number of organ dysfunctions (P < 0·001) and the incidence of subsequent new failures. The PTX3 concentration dropped from day 1 to 7, but this decrease was less pronounced in patients with septic shock (P = 0·0004). Higher concentrations of PTX3 on day 1 predicted incident organ dysfunctions. Albumin supplementation was associated with lower levels of PTX3 in patients with septic shock (P = 0·005) but not in those without shock. In a fully adjusted multivariable model, PTX3 on day 7 predicted 90-day mortality. Smaller drops in PTX3 predicted higher 90-day mortality. Conclusions: In severe sepsis and septic shock, early high PTX3 predict subsequent new organ failures, while a smaller drop in circulating PTX3 over time predicts an increased risk of death. Patients with septic shock show lower levels of PTX3 when assigned to albumin than to crystalloids.

Original languageEnglish
Pages (from-to)73-83
Number of pages11
JournalEuropean Journal of Clinical Investigation
Issue number1
Publication statusPublished - Jan 1 2017


  • Albumin
  • pentraxin 3
  • prognosis
  • septic shock
  • severe sepsis

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry
  • Clinical Biochemistry


Dive into the research topics of 'Pentraxin 3 in patients with severe sepsis or shock: the ALBIOS trial'. Together they form a unique fingerprint.

Cite this